News Website

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC - CancerNetwork

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC CancerNetwork

Published: June 17, 2025, 6:09 p.m.

Read Full Article

and poor overall patient survival in - ResearchGate

and poor overall patient survival in ResearchGate

Published: May 11, 2025, 2:51 a.m.

Read Full Article

DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer - Nature

DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer Nature

Published: May 10, 2025, 10:19 a.m.

Read Full Article

Uterine Cancer Survival Varies Widely by Race Across US - Medscape

Uterine Cancer Survival Varies Widely by Race Across US Medscape

Published: May 7, 2025, 12:27 p.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 5:25 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 18, 2025, 12:16 a.m.

Read Full Article

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to …

Published: April 17, 2025, 5:15 p.m.

Read Full Article

Latest Articles

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC - CancerNetwork

More evidence links physical activity with improved cancer survival - MSN

More Evidence Links Physical Activity With Improved Cancer Survival, New ACS Study Finds - American Cancer Society Press Room

More Evidence Links Physical Activity With Improved Cancer Survival, New ACS Study Finds | Newswise - Newswise

and poor overall patient survival in - ResearchGate

DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer - Nature

Uterine Cancer Survival Varies Widely by Race Across US - Medscape

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Latest Articles

Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC - CancerNetwork

More evidence links physical activity with improved cancer survival - MSN

More Evidence Links Physical Activity With Improved Cancer Survival, New ACS Study Finds - American Cancer Society Press Room

More Evidence Links Physical Activity With Improved Cancer Survival, New ACS Study Finds | Newswise - Newswise

and poor overall patient survival in - ResearchGate

DNA glycosylase (NEIL3) overexpression associated with low tumor immune infiltration and poor overall patient survival in endometrial cancer - Nature

Uterine Cancer Survival Varies Widely by Race Across US - Medscape

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - BioSpace

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - The Malaysian Reserve

Health Canada expands Jemperli (dostarlimab for injection) plus chemotherapy approval to all adult patients with primary advanced or first recurrent endometrial cancer, as the first and only immuno-oncology-based treatment to show an overall survival benefit - Yahoo Finance

Subscribe to Our Newsletter